Karyopharm Therapeutics (KPTI)
(Delayed Data from NSDQ)
$0.89 USD
+0.01 (0.73%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $0.88 -0.01 (-0.83%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
Balance Sheet
Fiscal Year End for Karyopharm Therapeutics Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 192 | 279 | 235 | 252 | 263 |
Receivables | 27 | 47 | 23 | 13 | 8 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 3 | 4 | 4 | 3 | 0 |
Other Current Assets | 12 | 20 | 14 | 9 | 7 |
Total Current Assets | 234 | 350 | 276 | 277 | 279 |
Net Property & Equipment | 1 | 1 | 2 | 2 | 3 |
Investments & Advances | 0 | 0 | 0 | 24 | 2 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 2 | 1 | 20 | 1 | 1 |
Total Assets | 240 | 358 | 305 | 313 | 295 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 3 | 2 | 4 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 61 | 58 | 69 | 53 | 41 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 2 | 2 | 1 | 1 | 3 |
Total Current Liabilities | 69 | 66 | 74 | 60 | 46 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 2 |
Convertible Debt | 171 | 170 | 169 | 118 | 110 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 133 | 133 | 133 | 73 | 74 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 377 | 375 | 385 | 263 | 245 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,351 | 1,328 | 1,099 | 1,120 | 923 |
Retained Earnings | -1,487 | -1,344 | -1,179 | -1,070 | -873 |
Other Equity | 0 | -1 | 0 | 1 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -136 | -17 | -80 | 51 | 50 |
Total Liabilities & Shareholder's Equity | 240 | 358 | 305 | 313 | 295 |
Total Common Equity | -136 | -17 | -80 | 51 | 50 |
Shares Outstanding | 114.50 | 113.20 | 75.50 | 73.60 | 62.70 |
Book Value Per Share | -1.19 | -0.15 | -1.06 | 0.69 | 0.79 |
Fiscal Year End for Karyopharm Therapeutics Inc falls in the month of December.
All items in Millions except Per Share data.
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 152 | 149 | 192 | 209 | 237 |
Receivables | 38 | 31 | 27 | 38 | 32 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 3 | 3 | 3 | 3 | 4 |
Other Current Assets | 15 | 15 | 12 | 13 | 18 |
Total Current Assets | 209 | 198 | 234 | 263 | 291 |
Net Property & Equipment | 1 | 1 | 1 | 1 | 1 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 2 | 2 | 2 | 1 | 0 |
Total Assets | 214 | 204 | 240 | 270 | 298 |
Liabilities & Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 5 | 3 | 1 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 50 | 55 | 61 | 56 | 52 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 2 | 2 | 2 | 2 |
Total Current Liabilities | 58 | 65 | 69 | 62 | 59 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 98 | 171 | 171 | 171 | 171 |
Long-Term Debt | 94 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 96 | 133 | 134 | 135 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 346 | 373 | 377 | 370 | 369 |
Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,369 | 1,356 | 1,351 | 1,346 | 1,340 |
Retained Earnings | -1,501 | -1,524 | -1,487 | -1,445 | -1,411 |
Other Equity | -1 | -1 | 0 | -1 | -1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -132 | -169 | -136 | -100 | -71 |
Total Liabilities & Shareholder's Equity | 214 | 204 | 240 | 270 | 298 |
Total Common Equity | -132 | -169 | -136 | -100 | -71 |
Shares Outstanding | 124.60 | 116.40 | 114.50 | 114.50 | 114.30 |
Book Value Per Share | -1.06 | -1.45 | -1.19 | -0.88 | -0.62 |